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Abstract
Background: In dengue-endemic countries, targeting limited control interventions to populations at risk of severe
disease could enable increased efficiency. Individuals who have had their first (primary) dengue infection are at risk
of developing more severe secondary disease, thus could be targeted for disease prevention. Currently, there is no
reliable algorithm for determining primary and post-primary (infection with more than one flavivirus) status from a
single serum sample. In this study, we developed and validated an immune status algorithm using single acute
serum samples from reporting patients and investigated dengue immuno-epidemiological patterns across the
Philippines.
Methods: During 2015/2016, a cross-sectional sample of 10,137 dengue case reports provided serum for molecular
(anti-DENV PCR) and serological (anti-DENV IgM/G capture ELISA) assay. Using mixture modelling, we re-assessed
IgM/G seroprevalence and estimated functional, disease day-specific, IgG:IgM ratios that categorised the reporting
population as negative, historical, primary and post-primary for dengue. We validated our algorithm against WHO
gold standard criteria and investigated cross-reactivity with Zika by assaying a random subset for anti-ZIKV IgM and
IgG. Lastly, using our algorithm, we explored immuno-epidemiological patterns of dengue across the Philippines.
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Results: Our modelled IgM and IgG seroprevalence thresholds were lower than kit-provided thresholds. Individuals
anti-DENV PCR+ or IgM+ were classified as active dengue infections (83.1%, 6998/8425). IgG− and IgG+ active
dengue infections on disease days 1 and 2 were categorised as primary and post-primary, respectively, while those
on disease days 3 to 5 with IgG:IgM ratios below and above 0.45 were classified as primary and post-primary,
respectively. A significant proportion of post-primary dengue infections had elevated anti-ZIKV IgG inferring
previous Zika exposure. Our algorithm achieved 90.5% serological agreement with WHO standard practice. Post-
primary dengue infections were more likely to be older and present with severe symptoms. Finally, we identified a
spatio-temporal cluster of primary dengue case reporting in northern Luzon during 2016.
Conclusions: Our dengue immune status algorithm can equip surveillance operations with the means to target
dengue control efforts. The algorithm accurately identified primary dengue infections who are at risk of future
severe disease.
Keywords: Dengue, Flavivirus, Primary, Post-primary, Immuno-epidemiology, Surveillance, Serology, Philippines
Background
Dengue has become the most significant disease-causing
arbovirus in the tropical and subtropical world. Accord-
ing to World Health Organization (WHO) global figures,
notified cases of dengue have increased 30-fold in the
past 5 decades [1], and a further 247,000 suspected den-
gue cases in the Western Pacific region were reported in
2014 compared to 2008 [2]. This reporting likely grossly
underestimated true numbers given the range of dengue
clinical manifestations and variable healthcare infrastruc-
tures in endemic countries. Instead, modelled estimates
approximate 390 million annual dengue cases occur glo-
bally, of which 75% are asymptomatic [3]. Dengue emer-
gence is believed to be attributed to rapid population
growth, urbanisation, human migration, climate change,
and is unhampered by costly control interventions [1].
Infection with one of the four known immunologically
distinct dengue virus serotypes (DENV1–4) causes a de-
layed increase in viremia, combined with potential fever,
which decreases within days. This is followed by an in-
crease in immunoglobulin M (IgM) that wanes over
months [4]. During a primary infection, immunoglobulin
G (IgG) increases during the convalescent stage of dis-
ease and persists for life, rendering individuals immune
to homologous but not heterologous dengue virus
serotypes. Upon a post-primary (secondary, tertiary,
quaternary) infection with a contrasting serotype, IgM
resurgence is subdued while pre-circulating, non-
neutralising IgG increases rapidly with viremia [5]. This
enhanced level of non-protective IgG is believed to
facilitate rapid viral replication in hosts through an
antibody-mediated enhancement (ADE) process [6, 7].
Dengue symptoms range from asymptomatic to severe
[3, 8]. According to WHO guidelines, severe symptoms
include critical plasma leakage, haemorrhage and organ
impairment [9]. These symptoms are thought to arise
from host-mediated cytokine storms that occur in re-
sponse to viral replication [10, 11], and as a
consequence, post-primary dengue infections are major
risk factors for developing severe disease [12–14].
The gold standard serological method for determining
a dengue infection, including whether it is primary or
post-primary dengue, remains the WHO haemagglutin-
ation inhibition assay (HIA) using acute and convales-
cent paired sera. A fourfold increase in IgG titre that
exceeds or falls below 1:2560 during convalescence is in-
dicative of secondary and primary infections, respectively
[15]. Despite the high-throughput nature of this tech-
nique, the need for paired sera, collected at least 7 days
apart, makes it undesirable for large-scale epidemio-
logical surveillance. To overcome this, commercial IgM
and IgG capture ELISAs, used concurrently, can distin-
guish primary and secondary dengue using a single
acute-stage serum sample. For instance, Panbio® capture
ELISAs (Alere, Brisbane, Australia, Cat. No.: 01PE10/
01PE20) state their IgG seroprevalence threshold of 22
panbio units corresponds to a HAI 1:2560 IgG titre.
Therefore, individuals assayed using these kits who are
IgM+/IgG− and IgM+/IgG+ supposedly represent pri-
mary and secondary dengue infections, respectively.
For dengue surveillance purposes, IgM and IgG cap-
ture ELISAs are an affordable and logistically simple way
to investigate epidemiological patterns in primary and
post-primary dengue. However, this technique is not
without caveats. First, given the delay in eliciting anti-
DENV IgM following infection, it remains unknown
whether early stage, non-immunogenic (IgM− and IgG
−), primary dengue cases are detectable using this solely
serological diagnostic. Second, given a recent study
highlighted primary dengue infections can elicit high
IgG levels during the febrile period [16], commercially
provided IgG thresholds may misclassify acute primary
and post-primary dengue infections. The incorporation
of commonly used molecular (PCR) tools may improve
the diagnostic capability of this algorithm. In addition,
IgG:IgM ratios have been proposed as useful metrics for
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categorising dengue immune status given that major dif-
ferences between IgG and IgM occur during post-
primary, compared to primary, infections [17, 18]. How-
ever, the practical application of these thresholds during
the febrile stage of infection is limited [16], suggesting
that further studies investigating the stage of infection at
which ratios become appropriate, if at all, are warranted.
In dengue-endemic countries including the
Philippines, optimising the use of passively collected
dengue case report data could strengthen disease surveil-
lance and control. In the Philippines, laboratory-based
surveillance efforts currently include routine molecular
characterisation of dengue, using sera collected from a
representative sample of all case reports. This allows
surveillance operations to monitor spatio-temporal den-
gue serotype patterns across the Philippines. However,
molecular characterisation alone does not indicate
whether case reports experienced primary or post-
primary dengue infections, information that may prove
useful in identifying populations at risk of severe symp-
toms. The aim of this study was to develop a novel den-
gue immune status algorithm using routinely collected
serological and molecular metrics and compare its per-
formance with commercial and WHO-approved prac-
tice. The co-circulation of other arboviruses across the
Philippines however, which present with similar acute
clinical manifestations, including Chikungunya [19, 20],
Japanese encephalitis [21] and more recently Zika in
2016 [22], poses a challenge to this effort. Numerous
studies have demonstrated antibody responses against
dengue virus cross-react with Zika virus [23–25], making
it difficult to detect the true causative agent of infection.
Upon validation of an appropriate immune status algo-
rithm, we investigated immuno-epidemiological patterns
of dengue transmission across the Philippines in 2015/
2016 to inform surveillance operations and targeted
disease control.
Methods
Dengue surveillance in the Philippines
The Philippines, consisting of 7641 islands spanning
more than 300,000 km2, is one of the countries in the
Western Pacific region most heavily burdened by dengue
[2]. According to the country’s Department of Health
(DOH), all four serotypes of dengue (DENV1–4) co-
circulate in the country and reported cases increased
from 213,930 to 220,518 between 2015 and 2016, re-
spectively [26]. In 2008, the Philippine Integrated
Disease Surveillance and Response (PIDSR) system was
established to synchronise and strengthen disease
surveillance across the country resulting in dengue be-
coming notifiable across all Filipino disease-reporting
units (DRUs), ranging from local barangay health facil-
ities to major regional hospitals [27]. According to the
2009 WHO criteria [9], the PIDSR categorises patients
as having no warning signs, warning signs or severe den-
gue symptoms. Warning signs include a sudden acute
illness coupled with either abdominal pain, vomiting,
fluid accumulation, mucosal bleeding, lethargy, liver en-
largement, increased haematocrit and/or decreased
platelet counts. Severe symptoms include a sudden acute
illness coupled with either severe plasma leakage, severe
bleeding and/or severe organ impairment.
Data collection, management and laboratory methods
Serum samples were collected from suspected dengue
cases that reported to DRUs (health facilities) across the
Philippines according to PIDSR criteria: a previously well
person with a 2–7-day prolonged febrile illness coupled
with two additional non-specific dengue symptoms. In-
fants under the age of 6 months were excluded from the
study due to the potential persistence of maternal anti-
DENV antibodies. A total of 20 sentinel and 185 non-
sentinel DRUs across the Philippines participated in the
study during 2015 and 2016. Sentinel DRUs supplied 5
random samples per week and included major regional
hospitals. Non-sentinel DRUs included any health facility
that reported a marked increase in dengue cases/deaths
according to PIDSR criteria [27] and supplied samples
during these outbreak periods. In total, 10,137 individ-
uals supplied serum to the National Reference Labora-
tory for Dengue and Other Arboviruses at the Research
Institute for Tropical Medicine (RITM), the research
arm of the DOH, for further study. Coupled with sera
were epidemiological data consistent with the PIDSR
system including age, sex, date of birth, date of admis-
sion, date of illness onset, symptoms (no warning signs,
warning signs and severe), outcome (dead and alive) and
DRU address and GPS coordinates. Additionally gener-
ated variables include disease day (date of admission–
date of illness onset), IgG:IgM ratio (IgG panbio units/
IgM panbio units), DRU elevation (metres) and DRU
population density (km2). DRU-level covariates were
generated using 100 m resolution Philippine elevation
and population density raster data from 2015 (USGS;
earth explorer; USA). Raster values were assigned to the
midpoint of the DRUs using corresponding GPS coordi-
nates in ArcGIS (v.10.5).
To focus this study on acute (febrile) dengue cases,
those who reported more than 5 days post the onset of
febrile symptoms (1318/10,137) or had missing onset/
reporting date data (154/10,137) were excluded from the
study. Subsequently, those with incomplete serological/
molecular data (131/8665) or symptom data (176/8665)
were excluded from the final dataset (Additional file 1).
Those with missing serological/molecular data were ex-
cluded as our algorithm utilises both molecular and
serological metrics. To assess whether excluding those
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with missing data among the febrile surveillance dataset
introduced selection bias, we compared percentage
demographic characteristics of the final febrile dengue
surveillance and those with missing serological/molecu-
lar and symptom data. To investigate whether anti-
DENV responses cross-react with Zika, a random subset
of serum samples from the final 2016 febrile dengue
surveillance dataset (1000/3921) were selected for anti-
ZIKV IgM and IgG assay.
Serum samples were stored at − 80 °C prior to molecu-
lar and serological assay. Among all viable collected
samples, dengue viremia was determined using a four-
plex real-time polymerase chain reaction (PCR) assay as
previously described [28]. In short, dengue serotype-
specific primers detect then amplify dengue RNA in
serum to determine viremia. Samples were considered
PCR positive or negative for dengue if they had critical
threshold cycle (Ct) values below or above 36, respect-
ively. To detect the presence of anti-dengue IgG and
IgM, samples were assayed using Panbio® capture IgM
and IgG ELISA kits (Cat. No.: 01PE10/01PE20, Alere,
Brisbane, Australia). Briefly, kits encompass antigen cap-
able of capturing host antibody specific to all four den-
gue serotypes and include plate-specific calibrators that
normalise output optical density (OD) readings to gener-
ate standardised antibody panbio units. Pre-determined
panbio unit serological thresholds categorised individ-
uals as negative (IgM ≤ 9, IgG ≤ 18), equivocal (IgM 9–
11, IgG 18–22) and positive (IgM ≥ 11, IgG ≥ 22) for
dengue infections. Consistent with kit specifications,
algorithm 1 (A1) classified primary and post-primary
dengue cases as being IgM+, IgG− and IgM+, IgG+, re-
spectively. Among samples selected for ZIKV antibody
testing, samples were assayed using Euroimmune™
(Lübeck, Germany) ZIKV IgM-ELISA (El 2668–9601 M)
and IgG-ELISA (El 2668–9601 G) kits according to
specification instructions. The semi-quantitative ratio
outputs from these tests were used to dichotomise indi-
viduals as anti-ZIKV IgM/IgG positive (OD ratio > 1.1)
or negative (OD ratio < 1.1).
Serological modelling and algorithm validation
Mixture models were used to (1) establish true anti-
dengue IgM and IgG seroprevalence and (2) determine,
disease day-specific, IgG:IgM ratio thresholds that distin-
guish primary from post-primary dengue infections. All
models were fitted by maximum likelihood with lognor-
mal distributions using the command ‘fmm:glm’ in
STATA (v.15, Texas, USA). For IgM and among the
entire study population, models were fitted with 3 com-
ponents to represent the seronegative, primary and post-
primary populations. For IgG and among non-active
DENV cases (PCR− and IgM−), the models were fitted
with 2 components to characterise distributions of those
with/without prior IgG exposure to DENV. We com-
pared these models based on a single distribution
models using Akaike information criterion (AIC). Lower
AIC indicates better model fit. IgM and IgG
seroprevalence thresholds refer to the lowest antibody
titre values with a classification probability of being
seropositive>seronegative.
To determine the primary and post-primary dengue
immune status of active dengue cases, disease day-
stratified IgG:IgM ratio distributions were fitted with 2-
component mixture models to classify the distinct
primary and post-primary subpopulations. For each dis-
ease day, we calculated IgG:IgM ratio thresholds corre-
sponding to the lowest ratio value with a classification
probability of being post-primary>primary. Active den-
gue cases with ratios above and below these disease day-
specific thresholds were categorised as post-primary and
primary, respectively. To determine whether IgG:IgM ra-
tios were appropriate to distinguish immune status on
specified disease days, we justified the existence of two
rather than one ratio distribution using Akaike informa-
tion criterion. Only 2-component models with lower
AIC values compared to 1-component models were used
to generate ratio thresholds for specific disease days.
To validate the commercial and novel dengue immune
status algorithms, we utilised paired sera from commu-
nity household members of reporting DENV RDT NS1+
patients involved in a study conducted in Nha Thang,
Vietnam. Twenty-one household members reported day
of fever and supplied acute and convalescent sera. Paired
sera were assayed for anti-DENV NS1 (Rapid diagnostic
test, Bio-Rad, France), IgM and IgG using Panbio® cap-
ture ELISA kits (as described previously). Using single
acute serum samples from household members, dengue
immune status was determined according to Panbio®
specifications (A1) and our novel algorithm (A2). In
addition, using paired sera from household members,
dengue immune status was also established correspond-
ing to WHO guidelines [22] (as described previously).
The serological agreement of both A1 and A2 to the
gold standard WHO technique was used to verify algo-
rithm performance for further use characterising
immuno-epidemiological trends in dengue transmission
across the Philippines.
To investigate dengue transmission intensity across
the Philippines, we estimated anti-DENV IgG serocon-
version rates (SCRs) among those reporting with non-
active dengue infections (PCR− and IgM−). SCRs, which
correspond to the average annual rate individuals sero-
convert from anti-DENV IgG− to IgG+, were obtained
from IgG age-seroprevalence curves fitted using simple
and reversible catalytic models. Assuming individuals
seroconvert solely from IgG seronegative to seropositive
status, Eq. 1 estimates the probability of being IgG
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seropositive at specified ages (a) by fitting a constant
force of infection parameter (λ) by least squares accord-
ing to the function:
P að Þ ¼ 1 − exp − λa  ð1Þ
Given immunological protection may decay over time
resulting in reporting non-active dengue cases reverting
to IgG seronegative status according to our mixture
model threshold, Eq. 2 fits an additional constant serore-
version parameter (ρ), by least squares, according to the
function:
P að Þ ¼ λ




Likelihood ratio tests were used to determine which
model, simple or reversible, best characterised age-IgG
seroprevalence data (p value < 0.05). All models were fit-
ted by maximum likelihood using a constrained/uncon-
strained ‘revcat’ command in STATA (v.15).
To investigate the risk factors associated with present-
ing as a post-primary, rather than a primary, dengue
case, we calculated unadjusted odds ratios from a uni-
variable logistic regression model using the ‘logit’ com-
mand in STATA (v.15). Explanatory variables included
age, sex, disease day, clinical manifestation, DRU eleva-
tion and DRU population density.
Results
Data description
Between 2015 and 2016, 8665 serum samples were col-
lected from consenting febrile, suspected dengue cases
among DRUs across the Philippines, in which 131/8665
and 176/8665 had missing molecular/serological and
symptom data, respectively (Additional file 1). Similar
demographic characteristics were observed between
febrile dengue cases with complete data and those with
incomplete molecular/serological and symptom data
(overlapping 95% CIs) (Additional file 2). In the final
complete dengue surveillance dataset used in this study,
demographic information reveals that a slightly higher
percentage were male (52.5%), whereas most were aged
between 6 and 15 years (44.1%), reported with dengue-
like symptoms (69.5%) and reported 3–4 days post the
onset of fever (60.5%). Mortality was low among the
study population with only 0.4% reported as having died
from dengue (Additional file 2).
Determining dengue immune status
Upon re-assessing anti-DENV IgM seroprevalence, we
identified a large proportion of the study population had
elevated anti-DENV IgM titres resulting in a distribution
best characterised by a 3-component, rather than a 1-
component, mixture model (AIC difference − 221.2)
(Additional file 3). This model provided an anti-DENV
IgM seropositivity threshold of 9.9 panbio units, result-
ing in an IgM seroprevalence of 71.8% (6050/8425) in
our population (Fig. 1A). To investigate whether our
anti-DENV IgM seroprevalence threshold is representa-
tive of all ages, among those aged between 0–5, 6–15,
16–30 and 31+ years, we estimated narrow-ranging anti-
DENV IgM seroprevalence thresholds of 9.8, 10.1, 10.3
and 9.7 panbio units, respectively (Additional file 4).
Given anti-DENV IgM responses shortly succeed
viremia during a dengue infection, we concluded those
either PCR+ for DENV RNA or anti-DENV IgM+ repre-
sent active dengue cases (83.1%, 6998/8425) while those
anti-DENV PCR− and anti-DENV IgM− represent non-
active dengue cases (misdiagnoses 16.9%, 1427/8425).
To re-assess anti-DENV IgG seropositivity, among
non-active dengue cases, we assumed two subpopula-
tions of those with/without previous IgG exposure to
dengue. Rationale supported by the fact a proportion of
non-active dengue cases had elevated anti-DENV IgG
(Fig. 1B) resulting in a 2-component, rather than a 1-
component, mixture model better characterising the IgG
panbio unit distribution (AIC difference − 97.7) (Add-
itional file 5). Furthermore, a higher proportion of older
non-active dengue cases had elevated IgG compared to
younger non-active dengue individuals (Additional file
4). A trend likely attributed to older individuals having a
higher probability of being infected with a previous den-
gue infection prior to reporting than younger individ-
uals. By fitting a 2-component mixture model to the IgG
panbio unit distribution of active dengue cases, this
yielded a IgG seroprevalence of 2.2 panbio units; non-
active dengue cases with IgG panbio units above and
below this value were categorised as having historical
(69.4%, 991/1427) and negative (30.6%, 436/1427) den-
gue exposure, respectively. Compared to kit-defined
thresholds, modelled anti-DENV IgM and IgG thresh-
olds were 1.1 and 19.8 panbio units lower, respectively.
Among active dengue cases, we determined primary
and post-primary dengue immune status by investigating
functional, disease day-specific, IgG:IgM ratio distribu-
tions (Fig. 2). With increasing disease day (1 to 5), we
observed two increasingly distinct lower and higher ratio
subpopulations consistent with predicted primary and
post-primary dengue infections, respectively (Fig. 2a).
These distributions were best fit by a 1-component mix-
ture model on disease days 1 and 2, and a 2-component
mixture models on disease days 3–5 (Additional file 6).
For disease days 3 to 5, IgG:IgM ratio thresholds, corre-
sponding the lowest ratio with a classification probability
of being post-primary>primary, equated to 0.44, 0.44
and 0.47, respectively (Fig. 2b, c). Given the similarity
between thresholds, disease day 3–5 ratio thresholds
were averaged (0.45) and incorporated into algorithm 2
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to distinguish primary and post-primary dengue infec-
tions. Active dengue cases on disease days 3–5 with IgG:
IgM ratios above and below 0.45 were categorised as
post-primary and primary dengue, respectively. For dis-
ease days 1–2, with no statistical justification for the ex-
istence of two distinct primary and post-primary ratio
distributions (1-component AIC<2-component AIC), we
opted to determine dengue immune status using the
previously calculated IgG seroprevalence threshold. Ac-
tive dengue cases on disease day 1 or 2 with IgG panbio
units above and below 2.2 were categorised as post-
primary and primary, respectively. An outline of algo-
rithm 2 (A2) is summarised in Fig. 3 while A1 and A2
study population categorisation is shown in Table 1.
After generating our novel dengue immune algorithm
(A2), we compared it to commercial practice (A1). A2
assigned dengue immune status to an additional 35.1%
(2955/8425) of the study population who were
unclassifiable according to A1 (Table 1). Among the 21
household fever cases, A2 categorised the immune status
of all members while A1 only classified 9/21 individuals.
Subsequently, we investigated how well each algorithm
categorised the immune status of household fever cases
with paired sera according to the WHO gold standard
method. A2 and A1 achieved 90.5% (19/21) and 71.4%
(15/21) serological agreement, respectively (Additional
files 7 and 8). These results demonstrate the superiority
of A2 compared to A1 and justified its use for investigat-
ing immuno-epidemiological patterns of dengue im-
mune status across the Philippines.
Lastly, to assess whether humoral responses against
dengue were attributed to other flaviviruses, we investi-
gated anti-ZIKV and anti-DENV cross-reactivity among
those categorised as primary and post-primary according
to A2 (Additional file 9). Among both primary and post-
primary dengue infections, anti-ZIKV IgM responses
Fig. 1 Determining anti-DENV IgM and IgG seroprevalence among the study population. A1 Histogram of study population anti-DENV IgM
panbio units. Red dash: Panbio® seroprevalence threshold (11 panbio units). A2 Mixture model of anti-DENV IgM panbio units with 3 components
representing IgM seronegative, primary and post-primary subpopulations. A3 Modelled classification probability curves of being anti-DENV IgM
seronegative or seropositive. Black dash: lowest IgM panbio unit with a classification probability of being seropositive>seronegative (9.9 panbio
units). B1 Histogram of anti-DENV IgG panbio units stratified by active/non-active DENV status. Red dash: Panbio® seroprevalence threshold (22
panbio units). B2 Mixture model of anti-DENV IgG titres among non-active DENV cases with 2 components representing IgG seronegative and
seropositive subpopulations. B3 Modelled classification probability curves of being anti-DENV IgG seronegative or seropositive. Black dash: lowest
IgG panbio units with a classification probability of being seropositive>seronegative (2.2 panbio units)
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Fig. 2 Determining primary and post-primary DENV immune status among active DENV cases. a Histogram of individual IgG:IgM ratios among
active DENV cases by disease day. b Mixture model of IgG:IgM ratio distributions with 2 components representing primary and post-primary
subpopulations. c Modelled classification probability of being a primary or post-primary DENV case by disease day. Black dash: lowest ratio value
with a classification probability of being post-primary>primary (Dd3, 0.44; Dd4, 0.44; Dd5, 0.47). N/A, no statistical justification for two mixture
model components (1-component model AIC<2-component model AIC); Dd, disease day
Fig. 3 Algorithm 2 (A2): dengue immune status algorithm. Criteria used to determine the dengue immune status of the study population across
the Philippines during 2015–2016. Primary DENV, current dengue infection with no previous flavivirus infection; post-primary DENV, current
dengue infection with at least one previous flavivirus infection
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were low and only 0% (0/154) and 1% (5/508) were IgM
seropositive, respectively, according to Euroimmune
specifications. This suggests very few of the active DENV
infections were recent ZIKV infections. In contrast,
among post-primary infections, anti-ZIKV IgG responses
were elevated with 23% (118/508) seropositive to anti-
ZIKV IgG according to Euroimmune kit instructions.
Together, these results suggest post-primary cases in-
clude current dengue infections with potential, historical,
ZIKV exposure (Fig. 3).
Dengue transmission dynamics
To investigate the temporal kinetic infection patterns
during acute primary and post-primary dengue infec-
tions, we calculated the mean anti-dengue viremia (Ct),
IgM and IgG titres by disease day (Fig. 4). During the
first 5 days of reported disease, mean IgM and IgG titres
increased among both primary and post-primary infec-
tions, although IgG titres were very low among primary
dengue infections. In contrast, mean dengue viremia
decreased (increasing Ct) during the first 5 days of dis-
ease among primary and post-primary infections, al-
though overall, this was significantly lower among post-
primary infections.
Among active dengue cases, we investigated potential
risk factors associated with post-primary compared to
primary dengue status (Table 2). Individual risk factors
included age (31+ compared to 0–5 years: OR 1.91
[1.54–2.38], p value < 0.001) and presenting with severe
symptoms (severe compared to no warning signs: OR
1.66 [1.28–2.16], p value < 0.001) or warning signs
(warning signs compared to no warning signs: OR 1.47
[1.28–1.70], p value < 0.001). DRU-level risk factors in-
clude decreasing ground elevation (150+ compared to
0–75 m: OR 0.61 [0.52–0.72], p value < 0.001) and in-
creasing population density (200+ compared to 0–100
km2: OR 1.32 [1.14–1.53], p value < 0.001) consistent
with the known epidemiology of dengue transmission.
The strong univariate association between post-primary
dengue and age prompted us to explore fine-scale age
trends with dengue immune status. According to per-
centage trends, those aged between 0.5 and 1 year with
active dengue infections were more likely to be primary,
rather than post-primary dengue cases. After which, the
percentage of those reporting with primary dengue
decreased with age while post-primary dengue cases
increased, plateaued then decreased with age. Among
non-active dengue cases, the percentage reporting with
negative and historical dengue were mainly younger and
older, respectively (Fig. 5a).
Lastly, we explored spatio-temporal trends of dengue
transmission dynamics across the Philippines during
2015 and 2016. Upon investigating dengue transmission
intensity across the country, we revealed a reversible







n % n %
Primary 1285 15.3 1576 18.7
Post-primary 4177 49.6 5414 64.3
Historical – – 991 11.8
Negative – – 436 5.2
Unclassifiable 2963 35.2 8 0.1
Algorithm 1 (A1): Panbio® commercial algorithm. Algorithm 2 (A2): novel
algorithm generated in this study
Fig. 4 Primary and post-primary temporal infection kinetics. Disease day-specific, averaged, infection kinetics (Ct value, IgM and IgG panbio units)
among acute active primary and post-primary dengue infections according to algorithm 2. Shading: 95% CI
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versus a simple, catalytic model best fits the age-
seroprevalence data among reporting non-active dengue
cases (Lrtest p value < 0.001). Using this statistically
favoured model, we estimated a seroconversion rate of
0.17 [95% CI 0.14–0.20] among all non-active dengue re-
ported cases (Fig. 6). Assuming individuals seeking care
are representative of the general population, this sug-
gests that 17% of the population were exposed to dengue
annually. Additionally, bi-monthly percentage trends re-
vealed temporal stability in the immune status of the
reporting population across the Philippines between
2015 and 2016, with the majority reporting being post-
primary cases (Fig. 5b). Despite this, we observed spatio-
temporal heterogeneity in the immune status of the
reporting population at lower administrative levels. In
northern Luzon provinces during 2016, a higher per-
centage of primary cases reported compared to the rest
of the Philippines (Fig. 5c).
Discussion
In this study, we generated and validated a novel
algorithm capable of distinguishing primary and post-
primary immune status among reporting, suspected den-
gue cases during the first 5 days of fever using a single
serum sample. By incorporating molecular and sero-
logical metrics, redefining dengue antibody exposure
and using IgG:IgM ratios at appropriate stages of infec-
tion, we were able to propose a dengue immune status
algorithm that was superior to existing practice. Subse-
quently, we demonstrated how the algorithm can be
applied for dengue surveillance purposes across the
Philippines. We revealed that post-primary dengue cases,
who are at higher risk of progressing to severe out-
comes, appear to be older than primary infections and
were more likely to report to health facilities in low
lying, urban areas. In addition, we showed primary den-
gue infections, who are at risk of subsequent post-
primary infections in future years, spatially clustered
around the northern regions of the Philippines in 2016.
According to a solely serological commercial immune
status algorithm, a large percentage of the study popula-
tion were unclassifiable. This shortcoming was overcome
by incorporating individual molecular metrics into our
novel algorithm, which captured early stage, non-
immunogenic, primary dengue infections. Our algorithm
also redefined seroprevalence to IgM and IgG using mix-
ture modelling. We questioned whether febrile primary
infections could exceed the standard IgG threshold, as
previously demonstrated [16], and were concerned with
determining the immune status of non-active dengue
cases that may have elevated anti-DENV IgG following
previous dengue exposure. Upon redefining serological
exposure to anti-DENV IgM and IgG, we classified those
with active dengue infections as being either IgM or
PCR positive given both rise and fall respectively during
an active dengue infection [4, 5]. As dengue IgM persists
for months following infection [4, 29], it could be argued
our algorithm categorises recent dengue infections as
active infections. However, elicited IgM provides
temporary immunity to other serotypes and the study
population included those seeking healthcare, so we con-
sidered it unlikely for individuals to seek treatment with
dengue-like symptoms for a past infection. In this study,
antibody seroprevalence corresponded to the lowest
panbio units with > 50% probability of being seropositive
according to mixture models. As a result, some individ-
uals with panbio units close to the generated thresholds
may have been misclassified. However, given the two-
tiered nature of our immune status algorithm, thresholds
offer the most practical solution for categorising the
study population.
We used disease day-specific IgG:IgM ratios to charac-
terise primary and post-primary dengue status as day of
Table 2 Risk factors associated with post-primary, opposed to
primary, active dengue immune status
Risk factor Post-primary
OR 95% CI p value
Age
< 5 1
6–15 1.69 1.46–1.96 < 0.001
16–30 1.80 1.53–2.11 < 0.001
> 31 1.91 1.54–2.38 < 0.001
Sex
Female 1
Male 0.94 0.85–1.04 0.248
Disease day
1–2 1
3–4 1.06 0.94–1.19 0.377
5 1.00 0.84–1.19 0.973
Clinical manifestation
No warning signs 1
Warning signs 1.47 1.28–1.70 < 0.001
Severe 1.66 1.28–2.16 < 0.001
Non-disclosed 0.90 0.76–1.07 0.227
DRU elevation (metres)
0–75 1
75–150 0.81 0.67–0.97 0.023
150+ 0.61 0.52–0.72 < 0.001
DRU pop den (km2)
0–100 1
100–200 0.87 0.77–0.97 0.017
200+ 1.32 1.14–1.53 < 0.001
OR unadjusted odds ratio, Pop den population density, DRU
disease-reporting unit
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fever is a common variable in dengue surveillance world-
wide. As anti-DENV IgG is absent or very low during
febrile primary infections and pre-circulates in post-
primary infections due to previous dengue exposure [17,
29, 30], we concluded the observed lower and higher
IgG:IgM ratio distributions represented primary and
post-primary cases, respectively. Interestingly, early dur-
ing the febrile infection period, there was no statistical
justification for the existence of two ratio distribution
peaks, so we refrained from using antibody ratios before
disease day 3. This is consistent with previous findings,
which state antibody ratios are poor determinants of im-
mune status early during infection, likely due to low
antibody responses [16]. Instead for very early stage den-
gue infections, we opted to use our newly generated IgG
exposure threshold to assess primary and post-primary
Fig. 5 Immuno-epidemiological patterns associated with DENV immune status across the Philippines. a Percentage age trends in dengue
immune status among the study population. Shading: 95% CIs. b Bi-monthly percentage trends in dengue immune status among the study
population between 2015 and 2016. Shading: 95% CIs. c Provincial spatio-temporal percentage trends in primary dengue immune status among
active DENV cases reporting across the Philippines between 2015 and 2016. Provinces with less than 10 samples collected excluded. Dengue
immune status determined according to algorithm 2
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dengue given the delay in eliciting anti-DENV IgG dur-
ing primary infections. Together, these findings suggest
that the combination of IgG seroprevalence and IgG:
IgM ratio thresholds, at appropriate stages of infection,
is desirable for distinguishing dengue immune status
among febrile reporting cases. In our study, we adhered
to manufacturers’ specifications to ensure our algorithm
is compatible for dengue surveillance operations else-
where. However, improvements in assay performance,
including antibody avidity estimates, may further
enhance this immune status algorithm.
Compared to a commercial algorithm, our dengue im-
mune status algorithm had a stronger serological agree-
ment with the WHO gold standard method [22], which
demonstrated its suitability for dengue surveillance and
epidemiological analysis. It should be noted, however,
that observed serological discordance between our novel
algorithm (A2) and the WHO gold standard may be at-
tributed to temporal changes in dengue infection status.
Individuals categorised as negative or historical accord-
ing to A2 could be infected with dengue between the
paired sera interim and therefore be classified as primary
or post-primary, respectively, based on WHO criteria.
Overall, based on the short interval between acute and
convalescent dengue sera collections and the suitability
of A2, we found substantial agreement between A2 and
the WHO gold standard method.
In our study, we found a significant proportion of
post-primary dengue infections had serological evidence
of historical, yet not recent, ZIKV exposure. This sup-
ports the hypothesis that other, structurally homologous
flaviviruses, including ZIKV, elicit IgG responses that
serologically prime individuals for subsequent post-
primary, instead of primary, dengue infections. A finding
previously reported [31, 32]. However, due to unknown
specificities [23–25], we cannot exclude the possibility
commercial ELISA kits are detecting antibodies elicited
from more than one type of flavivirus. Therefore, we as-
sumed that post-primary dengue infections may have
been preceded by any flavivirus infection. Determining
whether cross-reactive antibody responses are attributed
to just one or both Zika and dengue infections remains
an area of ongoing investigation.
Following the immune status classification of our
study population, we reported contrasting disease day-
averaged infection kinetics among primary and post-
primary dengue cases consistent with previous studies
[16, 29, 33]. The observed, lower viremia during the
acute stage of post-primary, compared to primary, den-
gue infections has been previously reported [34, 35]. We
also revealed the majority of the reporting population
were post-primary dengue cases, as previously reported
in the Philippines [36], and likely a consequence of the
higher risk of more severe symptoms prompting more to
seek healthcare. We found lower ground elevation and
higher population density as risk factors for reporting
with post-primary infections among active dengue cases.
This is consistent with the rationale of favourable mos-
quito breeding conditions in lower (warmer) altitudes
and areas of high human population density promote
mosquito populations [37] and increase dengue trans-
mission intensity. However, geographical imbalances in
disease awareness and healthcare access, which we were
unable to adjust for in this study, may also influence this
association. Together with the serological validation,
these immuno-epidemiological patterns provided further
evidence our algorithm accurately characterised the im-
mune status of the study population.
Between 2015 and 2016, we estimated that 17% of our
study population became serologically exposed to den-
gue annually, which is consistent with the previous esti-
mated force of infection between 11 and 22% generated
in Cebu, central Philippines, in 2016 [36]. However,
given these cases passively reported, it could be specu-
lated those reporting with non-dengue fever were more
likely to seek treatment if they had previous dengue
infection(s) due to heightened symptom awareness.
Therefore, our estimates are likely a slight overesti-
mation of true dengue transmission intensity across the
Philippines. Moreover, spatio-temporal heterogeneity in
dengue transmission intensity [38–41] infers this na-
tional estimate is unlikely to be representative of lower
administrative areas in the Philippines. Among those
Fig. 6 Dengue transmission intensity among non-active dengue
cases across the Philippines between 2015 and 2016. Red dot:
observed age-IgG seroprevalence. Black solid line: predicted age-IgG
seroprevalence according to reverse catalytic model. Black dash line:
predicted age-IgG seroprevalence 95% CI. SCR, seroconversion rate
[95% CI]
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reporting with active dengue, dengue immune status
remained temporally stable across the country yet
spatially heterogeneous in northern Luzon. The northern
cluster of increased primary dengue reporting was pos-
sibly attributed to recent dengue emergence, previously
shown in Mexico [42], and/or above average healthcare
access/disease awareness. Either way, these reflect popu-
lations at risk of developing post-primary infections fol-
lowing a novel serotype invasion. Such areas may also be
worth targeting for control and/or enhanced disease
surveillance.
Conclusion
In this study, we constructed a framework to accur-
ately categorise the dengue immune status of a large
reporting population of suspected dengue cases across
the Philippines using routinely collected surveillance
metrics. Using our algorithm, we were able to investi-
gate detailed dengue transmission dynamics over
2 years and revealed target populations at risk of de-
veloping severe disease. It is hoped that laboratory
surveillance operations, in the Philippines and else-
where, can apply our framework to monitor primary
and post-primary infection epidemiology and inform
targeted dengue control.
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